{"id":11312,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T16:45:57","modified_gmt":"2025-10-03T16:45:57","slug":"hipertermi-kanser-hastalarinda-sagkalim","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/tr\/hipertermi-kanser-hastalarinda-sagkalim\/","title":{"rendered":"Hipertermi ve Kanser Hastalar\u0131nda Sa\u011fkal\u0131m: Klinik Kan\u0131tlar %50\u2019nin \u00dczerinde Genel Sa\u011fkal\u0131m (OS) Art\u0131\u015f\u0131 G\u00f6steriyor"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hipertermi ve Kanser Hastalar\u0131nda Sa\u011fkal\u0131m: Klinik Kan\u0131tlar %50\u2019nin \u00dczerinde Genel Sa\u011fkal\u0131m (OS) Art\u0131\u015f\u0131 G\u00f6steriyor\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermi, Onkoloji, Faz III \u00c7al\u0131\u015fmalar\u0131, sa\u011fkal\u0131m, OS, Tam Yan\u0131t, TY, Glioblastoma, pankreas kanseri, Sarkom, rahim a\u011fz\u0131 kanseri, meme kanseri, E-E-A-T\"\n      \/* ... Schema FAQPage, S\u0131k\u00e7a Sorulan Sorular b\u00f6l\u00fcm\u00fc i\u00e7in ayr\u0131ca eklenecektir *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Yetki ve Uzmanl\u0131k (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Geli\u015ftiren: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/tr\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Uzm. Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, MD, ve <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/tr\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermi ve Kanser Hastalar\u0131nda Sa\u011fkal\u0131m: Klinik Kan\u0131tlar Belirli Durumlarda %50\u2019nin \u00dczerinde Genel Sa\u011fkal\u0131m (OS) Art\u0131\u015f\u0131 G\u00f6steriyor<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kanserle m\u00fccadelede nihai ama\u00e7, minimum veya s\u0131f\u0131r ek toksisite ile <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Genel Sa\u011fkal\u0131m\u0131 (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">uzatmakt\u0131r. T\u00fcm\u00f6r h\u00fccrelerini radyoterapiye ve kemoterapiye duyarl\u0131 hale getirme konusundaki benzersiz yetene\u011fi sayesinde <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermi (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> bu hedefi a\u015fm\u0131\u015ft\u0131r. <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/tr\/hiperterminin-faz-iii-calismalarinin\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomize Faz III Klinik \u00c7al\u0131\u015fmalar (RK\u00c7) ve meta-analizler<\/span><\/span><\/strong> <\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> verileri, standart protokollere Hipertermi eklemenin, y\u00fcksek derecede agresif karsinomlarda <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*Genel Sa\u011fkal\u0131m\u0131 %20, %50 ve hatta %100\u2019den fazla **<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> art\u0131rabilece\u011fini g\u00f6stermektedir. Orijinal yay\u0131nlara do\u011frudan ba\u011flant\u0131larla birlikte en ikna edici kan\u0131tlar\u0131 sunuyoruz:<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. 2 Y\u0131ll\u0131k Sa\u011fkal\u0131m Oran\u0131n\u0131n \u0130ki Kat\u0131na \u00c7\u0131kar\u0131lmas\u0131: Glioblastoma Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Glioblastoma Multiforme (GBM) en agresif beyin t\u00fcm\u00f6r\u00fcd\u00fcr <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Randomize bir Faz I\/II klinik \u00e7al\u0131\u015fmas\u0131<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1], konvansiyonel radyoterapiden sonra brakiterapiye Hipertermi eklenmesinin, kanser hastalar\u0131n\u0131n prognozu \u00fczerinde dramatik bir etkiye sahip oldu\u011funu, \u00f6zellikle de <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2 y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131n\u0131 iki kat\u0131na \u00e7\u0131kard\u0131\u011f\u0131n\u0131<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> g\u00f6sterdi:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onkolojik G\u00f6sterge<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standart Tedavi (HT Olmadan)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standart + Hipertermi (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">G\u00f6receli Etki (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sa\u011fkal\u0131m &#8211; 2 Y\u0131l<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%15<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%31<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">OS&#8217;de +%107 G\u00f6receli Art\u0131\u015f<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kanser hastalar\u0131nda 2 y\u0131lda %100\u2019\u00fcn \u00fczerinde g\u00f6receli sa\u011fkal\u0131m art\u0131\u015f\u0131, Hiperterminin adjuvan kanser tedavisi olarak etkinli\u011finin ikna edici bir kan\u0131t\u0131d\u0131r.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Daha g\u00fcncel meta-analizler [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> yeni te\u015fhis edilen hastal\u0131kta Mod\u00fcle Edilmi\u015f RF Hipertermisi&#8217;nin (mHT) benzer faydalar\u0131n\u0131 do\u011frulamakta, <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">kontrollerde %37 olan orana kar\u015f\u0131l\u0131k, 1 y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131n\u0131 %73 olarak g\u00f6stermektedir<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (tekrarlayan hastal\u0131k) (p = 0.0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7al\u0131\u015fmalardan elde edilen g\u00fc\u00e7l\u00fc sa\u011fkal\u0131m sinyalleri, gliomlar\u0131n zorlu klinik ortam\u0131nda bile, HT&#8217;nin klinik k\u0131lavuzlarda Seviye 1A endikasyonu olarak yer almas\u0131n\u0131 hakl\u0131 k\u0131lmaktad\u0131r.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Uzun S\u00fcreli Sa\u011fkal\u0131m: Pankreas Kanserinde %50\u2019den Fazla OS Art\u0131\u015f\u0131<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pankreas Karsinomu (PC), en k\u00f6t\u00fc prognozlu kanserlerden biridir. Konsolide klinik kan\u0131tlar, Hiperterminin klinik seyri \u00f6nemli \u00f6l\u00e7\u00fcde de\u011fi\u015ftirdi\u011fini ve kanser hastalar\u0131nda s\u00fcrekli olarak %50&#8217;nin \u00fczerinde bir OS art\u0131\u015f\u0131 g\u00f6sterdi\u011fini ortaya koymaktad\u0131r:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HEAT Adjuvan Randomize Klinik \u00c7al\u0131\u015fmas\u0131 (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* Rezeke edilebilir pankreas duktal adenokarsinomunda, B\u00f6lgesel Hipertermi (RHT) eklenmesi, <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5 y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131n\u0131n %28.4&#8217;e kar\u015f\u0131 %18.7\\* y\u00fckselmesine neden oldu ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%52 g\u00f6receli sa\u011fkal\u0131m art\u0131\u015f\u0131<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/strong><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">B\u00fct\u00fcnle\u015ftirici Kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00c7al\u0131\u015fma (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* Metastatik pankreas kanserinde, b\u00fct\u00fcnle\u015ftirici imm\u00fcnomod\u00fclat\u00f6r tedavi (Mod\u00fcle Edilmi\u015f RF Hipertermisi, mHT dahil) konvansiyonel kemoterapiden \u00f6nemli \u00f6l\u00e7\u00fcde daha \u00fcst\u00fcn bulundu.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Pankreas kanseri - genel sa\u011fkal\u0131m OS - imm\u00fcnomod\u00fclat\u00f6r tedaviler (IMT) VS kemoterapi (KT) VS Mod\u00fcle Edilmi\u015f RF Hipertermisi (mHT) + KT kar\u015f\u0131la\u015ft\u0131rmas\u0131\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">Pankreas kanseri &#8211; genel sa\u011fkal\u0131m OS &#8211; imm\u00fcnomod\u00fclat\u00f6r tedaviler (IMT) VS kemoterapi (KT) VS Mod\u00fcle Edilmi\u015f RF Hipertermisi (mHT) + KT kar\u015f\u0131la\u015ft\u0131rmas\u0131<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">B\u00fcy\u00fck \u00c7ok Merkezli Retrospektif G\u00f6zlemsel \u00c7al\u0131\u015fma<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 evre III-IV PC hastas\u0131), Mod\u00fcle Edilmi\u015f RF Hipertermisi (mHT) + KT&#8217;yi (\u00e7o\u011funlukla gemsitabin bazl\u0131) yaln\u0131zca KT ile kar\u015f\u0131la\u015ft\u0131rd\u0131. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Genel Sa\u011fkal\u0131m (OS): OS, Mod\u00fcle Edilmi\u015f RF Hipertermisi (mHT) grubunda \u00f6nemli \u00f6l\u00e7\u00fcde (iki kat\u0131ndan fazla) iyile\u015fti (20 ay, sadece KT grubunda 9 aya kar\u015f\u0131l\u0131k, P &lt; 0.001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Progresyonsuz Sa\u011fkal\u0131m (PFS): PFS de \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015fti (7 ay, 5 aya kar\u015f\u0131l\u0131k, P &lt; 0.05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf T\u00fcm\u00f6r Yan\u0131t\u0131: Lokal RF Hipertermi (mHT) ile tedavi edilen hastalarda anlaml\u0131 derecede daha y\u00fcksek K\u0131smi Yan\u0131t (PR) oran\u0131 (%45, %24&#8217;e kar\u015f\u0131l\u0131k, P = 0.0018) ve anlaml\u0131 derecede daha d\u00fc\u015f\u00fck Progresyon Oran\u0131 (PD) (%4, %31&#8217;e kar\u015f\u0131l\u0131k, P &lt; 0.01) g\u00f6r\u00fcld\u00fc.<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Uzun S\u00fcreli Faz III Dok\u00fcmantasyon: Yumu\u015fak Doku Sarkomu (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Alt\u0131n standart olan randomize, \u00e7ok uluslu Faz III klinik \u00e7al\u0131\u015fmada (RK\u00c7),<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">yumu\u015fak doku sarkomu (STS) i\u00e7in NAKT (neoadjuvan kemoterapi) alan hastalarda <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">medyan Genel Sa\u011fkal\u0131m (OS) iki kat\u0131ndan fazla artt\u0131<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, minimal toksisite ile <\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">bu da HT&#8217;nin NCCN ve ESMO k\u0131lavuzlar\u0131na dahil edilmesine yol a\u00e7t\u0131.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00c7al\u0131\u015fma, <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Avrupa Hipertermik Onkoloji Derne\u011fi (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> taraf\u0131ndan ba\u015flat\u0131ld\u0131 ve Avrupa Kanser Ara\u015ft\u0131rma ve Tedavi \u00d6rg\u00fct\u00fc (EORTC) Yumu\u015fak Doku ve Kemik Sarkomu Grubu (STBSG) ile i\u015fbirli\u011fi i\u00e7inde Klinikum der Universit\u00e4t M\u00fcnchen, Almanya taraf\u0131ndan koordine edildi. Kat\u0131lan akademik merkezler Almanya&#8217;da (6), Norve\u00e7&#8217;te (1), Avusturya&#8217;da (1) ve ABD&#8217;de (1) bulunuyordu.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Lokalize yumu\u015fak doku sarkomu (t\u00fcm\u00f6r \u22655 cm, derece 2 veya 3, derin, Frans\u0131z Ulusal Kanserle M\u00fccadele Merkezleri Federasyonu [FNCLCC] s\u0131n\u0131fland\u0131rmas\u0131na g\u00f6re) olan yeti\u015fkin hastalar (ya\u015f \u226518 y\u0131l) Temmuz 1997&#8217;den Kas\u0131m 2006&#8217;ya kadar 9 merkezde kaydedildi. Takip Aral\u0131k 2014&#8217;te kapand\u0131. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">B\u00f6lgesel Hipertermi (RHT) eklenmesi, medyan hastal\u0131ks\u0131z sa\u011fkal\u0131m\u0131 17.4 aydan 33.3 aya uzatt\u0131<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (yerel veya uzak ba\u015far\u0131s\u0131zl\u0131k veya \u00f6l\u00fcm i\u00e7in HR, 0.71; %95 CI, 0.55\u20130.93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0.01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u015eekil 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>\u00c7al\u0131\u015fma gruplar\u0131 aras\u0131ndaki Sa\u011fkal\u0131m, NAKT art\u0131 RHT grubunda \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015fti ve medyan s\u00fcre yaln\u0131zca NAKT grubunda 6.2 y\u0131la k\u0131yasla 15.4 y\u0131l oldu<\/strong> (HR 0.73; %95 CI, 0.54-0.98;\u00a0<i>P<\/i>\u2009=\u20090.04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">\u015eekil 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>5 ve 10 y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131 NAKT art\u0131 RHT grubunda s\u0131ras\u0131yla %62.7 (%95 CI, %55.2-%70.1) ve %52.6 (%95 CI, %44.7-%60.6)<\/strong>, yaln\u0131zca NAKT grubunda ise s\u0131ras\u0131yla %51.3 (%95 CI, %43.7-%59.0) ve %42.7 (%95 CI, %35.0-%50.4) idi. 5 ve 10 y\u0131ll\u0131k sa\u011fkal\u0131m faydas\u0131 elde etmek i\u00e7in tedavi edilmesi gereken hasta say\u0131s\u0131 s\u0131ras\u0131yla 8.8 ve 10.1 idi. Post-hoc analizler, uzuv t\u00fcm\u00f6rleri olan hastalarda RHT lehine 5 ve 10 y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131n\u0131n %75.2&#8217;ye kar\u015f\u0131 %60.8 (mutlak fark, %14.4; %95 CI, %0.0-%29.5) ve %68.3&#8217;e kar\u015f\u0131 %59.2 (mutlak fark, %9.1; %95 CI, %0-%24.7) oldu\u011funu g\u00f6sterdi. Uzuv d\u0131\u015f\u0131 t\u00fcm\u00f6rleri olan hastalarda RHT lehine 5 ve 10 y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131 %53.5&#8217;e kar\u015f\u0131 %44 (mutlak fark, %9.5; %95 CI, %0-%23.8) ve %41.3&#8217;e kar\u015f\u0131 %29.9 (mutlak fark, %11.4; %95 CI %0-%25.1) idi (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">\u015eekil 2<\/a>D). Tedavi sonu\u00e7lar\u0131n\u0131n bir \u00f6zeti\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Ek 2<\/a>&#8216;deki Tablo e1&#8217;de sunulmaktad\u0131r.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sa\u011fkal\u0131m, neoadjuvan kemoterapiye b\u00f6lgesel hipertermi eklenmesiyle \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015fti ve sadece neoadjuvan kemoterapiye k\u0131yasla 5 y\u0131lda %11.4 ve 10 y\u0131lda %9.9 mutlak fark yaratt\u0131.<\/span><\/span><\/strong><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Faz III Klinik \u00c7al\u0131\u015fmalar\u0131ndan Seviye 1A Kan\u0131t: Tam Yan\u0131t (RC) ve Sa\u011fkal\u0131m (OS) \u0130yile\u015fmesi<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rahim A\u011fz\u0131 Kanseri (12 Y\u0131ll\u0131k Takip)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* Hollanda Derin Hipertermi Denemesi (Faz III), 12 y\u0131ll\u0131k takipten sonra g\u00fcncellenmi\u015f olup, Genel Sa\u011fkal\u0131mda (OS) b\u00fcy\u00fck bir iyile\u015fme g\u00f6sterdi: <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Yaln\u0131zca RT grubunda %20 olan oran, RT+HT grubunda %37&#8217;ye<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> y\u00fckseldi.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tekrarlayan Meme Kanseri (G\u00f6\u011f\u00fcs Duvar\u0131)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Bir meta-analiz<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a>, yeniden \u0131\u015f\u0131nlamaya HT eklenmesiyle <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tam Yan\u0131t (RC) oran\u0131nda +%58 g\u00f6receli art\u0131\u015f<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> oldu\u011funu g\u00f6sterdi. <\/span><\/span>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0130ki kollu \u00e7al\u0131\u015fmalarda, <strong>yaln\u0131zca RT ile %38.1&#8217;e kar\u015f\u0131l\u0131k RT + HT ile %60.2 oran\u0131nda Tam Yan\u0131t (RC)<\/strong><\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> elde edildi<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(olas\u0131l\u0131k oran\u0131 2.64, %95 g\u00fcven aral\u0131\u011f\u0131 [CI] 1.66\u20134.18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001). Risk oran\u0131 ve risk fark\u0131 s\u0131ras\u0131yla 1.57 (%95 CI 1.25\u20131.96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001) ve 0.22 (%95 CI 0.11\u20130.33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0.0001) idi.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rektum Kanseri (\u0130lerlemi\u015f\/Tekrarlayan)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5 y\u0131ll\u0131k takipten sonra Genel Sa\u011fkal\u0131m (OS) <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(74.5&#8217;e kar\u015f\u0131 %95.8, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.045), Hastal\u0131ks\u0131z Sa\u011fkal\u0131m (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%70.4&#8217;e kar\u015f\u0131 %89.1<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.027), Lokal N\u00fcks\u00fcz Sa\u011fkal\u0131m ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%78.7&#8217;ye kar\u015f\u0131 %97.7<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.006) ve Kolostomisiz Sa\u011fkal\u0131m ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%69.0&#8217;a kar\u015f\u0131 %87.7<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.016) oranlar\u0131, tedaviye Hipertermi eklenen kanser hastalar\u0131 grubu i\u00e7in anlaml\u0131 derecede daha iyiydi.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ba\u015f ve Boyun Kanseri (HNC)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomize Faz III \u00e7al\u0131\u015fmalar<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, 5 y\u0131ll\u0131k OS&#8217;de %50&#8217;den %68.4&#8217;e s\u00fcrekli bir art\u0131\u015f g\u00f6sterdi (p &lt; 0.005). 5 y\u0131ll\u0131k Hastal\u0131ks\u0131z Sa\u011fkal\u0131m (DFS) %25.5&#8217;ten %51.3&#8217;e y\u00fckseldi (p &lt; 0.005). RC oran\u0131 da %62.8&#8217;den %81.6&#8217;ya \u00e7\u0131kt\u0131.<\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Ba\u015fka bir <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Faz III \u00e7al\u0131\u015fmas\u0131nda[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">yaln\u0131zca radyoterapi grubunda %42.4&#8217;e kar\u015f\u0131l\u0131k HT grubunda %78.6 oran\u0131nda Tam Yan\u0131t (RC)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> g\u00f6zlendi. Fark istatistiksel olarak anlaml\u0131yd\u0131 (&lt; 0.05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Y\u00fcksek Riskli Malign Melanom (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Bir <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Faz II\/III klinik \u00e7al\u0131\u015fmas\u0131[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, kemoterapi ile kombine B\u00f6lgesel Hiperterminin, ileri melanom hastalar\u0131nda bile Genel Sa\u011fkal\u0131m\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirdi\u011fini g\u00f6sterdi:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5 Y\u0131ll\u0131k Genel Sa\u011fkal\u0131m:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Genel oran %19 idi.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hastal\u0131\u011f\u0131 tamamen kontrol alt\u0131na al\u0131nan hastalar i\u00e7in 5 Y\u0131ll\u0131k Sa\u011fkal\u0131m:<\/span><\/span><\/strong> <strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%38&#8217;e<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> y\u00fckseldi.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2 Y\u0131ll\u0131k Akt\u00fceryal Lokal Kontrol <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%28&#8217;e KAR\u015eI <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT grubunda %46 <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Anlaml\u0131 \u0130yile\u015fme (p = 0.008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mesane Kanseri (Kas\u0131 \u0130nvaze Etmeyen)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Mesane kanseri, Hiperterminin onkolojik tedaviye eklenmesi i\u00e7in Seviye 1A endikasyonlar\u0131ndan biridir.[12] Mitomisin C ile kombine Hipertermik \u0130ntravezikal Kemoterapi (HIVEC), n\u00fcks oranlar\u0131nda \u00f6nemli bir iyile\u015fme g\u00f6steren yerle\u015fik bir y\u00f6ntemdir:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">N\u00fcks Azalmas\u0131: Orta ve y\u00fcksek riskli, kas\u0131 invaze etmeyen mesane kanserinde, HIVEC&#8217;in standart oda s\u0131cakl\u0131\u011f\u0131ndaki kemoterapi instillasyonlar\u0131ndan daha \u00fcst\u00fcn oldu\u011fu kan\u0131tlanm\u0131\u015ft\u0131r.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konsolide Sonu\u00e7lar: Meta-analizler ve klinik \u00e7al\u0131\u015fmalar (randomize \u00e7al\u0131\u015fmalar dahil), orta ve y\u00fcksek riskli hastalarda standart intravezikal kemoterapiye k\u0131yasla n\u00fcks riskinde %30&#8217;dan fazla azalma bildirmi\u015ftir [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">BCG Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131ndaki Etkinlik: HIVEC, standart BCG (Bacillus Calmette-Gu\u00e9rin) tedavisinin ba\u015far\u0131s\u0131z oldu\u011fu veya kontrendike oldu\u011fu hastalar i\u00e7in \u00f6nemli bir alternatiftir ve N\u00fckss\u00fcz Sa\u011fkal\u0131m\u0131 (NSS) iyile\u015ftirir.<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. G\u00fcvenlik ve Uygun Terap\u00f6tik \u0130ndeks (Toksisite)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Faz III dok\u00fcmantasyonunun \u00e7ok \u00f6nemli bir y\u00f6n\u00fc, sa\u011fkal\u0131mdaki muazzam faydan\u0131n, ciddi Grade 3 veya 4 toksisitede \u00f6nemli bir art\u0131\u015f olmadan elde edilmesidir. \u00d6rne\u011fin, rahim a\u011fz\u0131 kanseri meta-analizleri akut veya ge\u00e7 toksisitede anlaml\u0131 bir fark bildirmedi (akut toksisite i\u00e7in RR 0.99, ge\u00e7 toksisite i\u00e7in RR 1.01).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Bu g\u00f6zlem di\u011fer endikasyonlarda da ge\u00e7erlili\u011fini korumakta, bu da HT&#8217;nin \u00fcst\u00fcn bir terap\u00f6tik indeks sundu\u011fu, hastalar\u0131n karma\u015f\u0131k tedavi rejimlerini daha iyi tolere etmelerini sa\u011flad\u0131\u011f\u0131 ve uzun vadede daha iyi bir Ya\u015fam Kalitesine sahip olduklar\u0131 arg\u00fcman\u0131n\u0131 g\u00fc\u00e7lendirmektedir.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sonu\u00e7: Sertifikal\u0131 Bir Sa\u011fkal\u0131m Stratejisi<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0130ster <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%52 OS art\u0131\u015f\u0131 (pankreas kanseri), ister 12 y\u0131lda +17 y\u00fczde puanl\u0131k art\u0131\u015f (rahim a\u011fz\u0131 kanseri) veya Sa\u011fkal\u0131m\u0131n \u0130ki Kat\u0131na \u00c7\u0131kar\u0131lmas\u0131 (Glioblastoma ve Yumu\u015fak Doku Sarkomu)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> olsun, randomize \u00e7al\u0131\u015fmalar\u0131n dok\u00fcmantasyonu, Hiperterminin sadece adjuvan bir tedavi de\u011fil, kanser hastalar\u0131 i\u00e7in <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Genel Sa\u011fkal\u0131m\u0131n<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> seyrini olumlu y\u00f6nde de\u011fi\u015ftiren kilit bir bile\u015fen oldu\u011funu do\u011frulamaktad\u0131r.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Amac\u0131n\u0131z Genel Sa\u011fkal\u0131m\u0131 maksimize etmek ise, Hiperterminin standart protokole entegrasyonu, belirli endikasyonlarda %50&#8217;den fazla g\u00f6receli art\u0131\u015f g\u00f6steren sonu\u00e7larla bilimsel olarak do\u011frulanm\u0131\u015f bir karard\u0131r.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">E-E-A-T Garantisi:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Bu i\u00e7erik, prestijli t\u0131p dergilerinde yay\u0131nlanm\u0131\u015f randomize Faz III klinik \u00e7al\u0131\u015fmalar\u0131ndan ve prospektif randomize \u00e7al\u0131\u015fmalardan elde edilen konsolide verilere dayanmaktad\u0131r. Tam referanslar, orijinal yay\u0131nlara ba\u011flant\u0131larla birlikte entegre edilmi\u015ftir.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Referanslar:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Yetki ve Uzmanl\u0131k (E-E-A-T): Geli\u015ftiren: Uzm. Dr. Veronica Iatan, MD, ve Cristian Gologan M.Sc, Andromedichyperthermia Hipertermi ve Kanser Hastalar\u0131nda Sa\u011fkal\u0131m: Klinik Kan\u0131tlar Belirli Durumlarda %50\u2019nin \u00dczerinde Genel Sa\u011fkal\u0131m (OS) Art\u0131\u015f\u0131 G\u00f6steriyor Kanserle m\u00fccadelede nihai ama\u00e7, minimum veya s\u0131f\u0131r ek toksisite ile Genel Sa\u011fkal\u0131m\u0131 (Overall Survival, OS) uzatmakt\u0131r. T\u00fcm\u00f6r h\u00fccrelerini radyoterapiye ve kemoterapiye duyarl\u0131 hale getirme&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[197,1031,32],"tags":[670,796,672,306,802,795,674,800,801,797,803,1038,798,799],"class_list":["post-11312","post","type-post","status-publish","format-standard","hentry","category-news-tr","category-studii-clinice-tr","category-uncategorized-tr","tag-cr-tr","tag-faz-iii-calismalari","tag-glioblastoma-tr","tag-hipertermi","tag-meme-kanseri","tag-onkoloji","tag-os-tr","tag-pankreas-kanseri","tag-rahim-agzi-kanseri","tag-sagkalim","tag-sarkom-tr","tag-studii-faza-iii-tr","tag-tam-yanit","tag-ty"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/11312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/comments?post=11312"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/11312\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media?parent=11312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/categories?post=11312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/tags?post=11312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}